These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 32474203)

  • 1. Shorter antibiotic regimens impact the control efforts in high tuberculosis burden regions of Taiwan.
    Lin YJ; Lin HC; Yang YF; Chen CY; Lu TH; Liao CM
    Int J Infect Dis; 2020 Aug; 97():135-142. PubMed ID: 32474203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of novel first-line treatment regimens for tuberculosis.
    Owens JP; Fofana MO; Dowdy DW
    Int J Tuberc Lung Dis; 2013 May; 17(5):590-6. PubMed ID: 23575322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa.
    Knight GM; Gomez GB; Dodd PJ; Dowdy D; Zwerling A; Wells WA; Cobelens F; Vassall A; White RG
    PLoS One; 2015; 10(12):e0145796. PubMed ID: 26717007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of treating multidrug-resistant tuberculosis.
    Resch SC; Salomon JA; Murray M; Weinstein MC
    PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis.
    Gomez GB; Dowdy DW; Bastos ML; Zwerling A; Sweeney S; Foster N; Trajman A; Islam MA; Kapiga S; Sinanovic E; Knight GM; White RG; Wells WA; Cobelens FG; Vassall A
    BMC Infect Dis; 2016 Dec; 16(1):726. PubMed ID: 27905897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba™ to background regimens in Germany.
    Diel R; Hittel N; Schaberg T
    Respir Med; 2015 May; 109(5):632-41. PubMed ID: 25862597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shortened Tuberculosis Treatment for People with HIV in South Africa. A Model-based Evaluation and Cost-effectiveness Analysis.
    Reddy KP; Horsburgh CR; Wood R; Fields NF; Girouard MP; Costantini S; Hou T; Freedberg KA; Walensky RP
    Ann Am Thorac Soc; 2020 Feb; 17(2):202-211. PubMed ID: 31689133
    [No Abstract]   [Full Text] [Related]  

  • 9. Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis.
    Ryckman TS; Schumacher SG; Lienhardt C; Sweeney S; Dowdy DW; Mirzayev F; Kendall EA
    Lancet Glob Health; 2024 Jun; 12(6):e995-e1004. PubMed ID: 38762299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospects for advancing tuberculosis control efforts through novel therapies.
    Salomon JA; Lloyd-Smith JO; Getz WM; Resch S; Sánchez MS; Porco TC; Borgdorff MW
    PLoS Med; 2006 Aug; 3(8):e273. PubMed ID: 16866578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population-level impact of shorter-course regimens for tuberculosis: a model-based analysis.
    Fofana MO; Knight GM; Gomez GB; White RG; Dowdy DW
    PLoS One; 2014; 9(5):e96389. PubMed ID: 24816692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drones and digital adherence monitoring for community-based tuberculosis control in remote Madagascar: A cost-effectiveness analysis.
    Bahrainwala L; Knoblauch AM; Andriamiadanarivo A; Diab MM; McKinney J; Small PM; Kahn JG; Fair E; Rakotosamimanana N; Grandjean Lapierre S
    PLoS One; 2020; 15(7):e0235572. PubMed ID: 32634140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries.
    Lu X; Smare C; Kambili C; El Khoury AC; Wolfson LJ
    BMC Health Serv Res; 2017 Jan; 17(1):87. PubMed ID: 28122562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-course prophylaxis against tuberculosis in HIV-infected persons. A decision and cost-effectiveness analysis.
    Rose DN
    Ann Intern Med; 1998 Nov; 129(10):779-86. PubMed ID: 9841583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model.
    Kendall EA; Shrestha S; Cohen T; Nuermberger E; Dooley KE; Gonzalez-Angulo L; Churchyard GJ; Nahid P; Rich ML; Bansbach C; Forissier T; Lienhardt C; Dowdy DW
    PLoS Med; 2017 Jan; 14(1):e1002202. PubMed ID: 28045934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis.
    Schnippel K; Firnhaber C; Page-Shipp L; Sinanovic E
    Int J Tuberc Lung Dis; 2018 Aug; 22(8):918-925. PubMed ID: 29991402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D; Dass R; Hettle R
    BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of tuberculosis infection in children.
    Hatzenbuehler LA; Starke JR
    Expert Rev Anti Infect Ther; 2018 Sep; 16(9):695-708. PubMed ID: 30132364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling the patient and health system impacts of alternative xpert® MTB/RIF algorithms for the diagnosis of pulmonary tuberculosis in Addis Ababa, Ethiopia.
    Tesfaye A; Fiseha D; Assefa D; Klinkenberg E; Balanco S; Langley I
    BMC Infect Dis; 2017 May; 17(1):318. PubMed ID: 28464797
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.